Strattera was generally well-tolerated. The most common side effects reported in the study were headache and the common cold (nasopharyngitis). In the study, the mean final dose of Strattera was approximately 1.54 mg/kg/day after 12 months and 18 months treatment. There were no significant differences in standardized height change between groups during the post-randomization period.
ADHD is the most common psychiatric disorder to appear in childhood. If left untreated, ADHD can have long-term effects on a child's emotional well-being and social skills, like making friends or doing well at school or at work.(2) ADHD can also have lifelong consequences, including poor peer relations, poor academic and work performance and increased risk-taking behaviors, such as substance abuse.(3)
It is not known precisely how Strattera reduces ADHD symptoms, but scientists believe it works by blocking or slowing reabsorption of norepinephrine, a chemical in the brain considered important in regulating attention, impulsivity and activity levels. This keeps more norepinephrine at work in the spaces between neurons in the brain. Improved efficiency in the norepinephrine system is associated with improvement in symptoms of ADHD.(4) Since its first approval in the United States in 2002, more than 5 million patients have taken Strattera worldwide. It has been studied in more than 6,000 patients in clinical trials, some for as long as three years.
Important Safety Information for Strattera(R) (atomoxetine HCl)
In some children and teens, Strattera increases the risk of suicidal
thoughts. A combined analysis of 12 studies of Strattera showed that in
children and teens this risk was 0.4% for those taking Strattera compared
to none for those taking a sugar pill. A similar analysis in adults treated
with Strattera did not reveal an increased risk of suicidal thoughts. Call
your doctor right away if your child has thou
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved